Vaxart, Inc(VXRT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VXRT Vaxart, Inc

未开盘 07-19 16:00:00 EDT

0.6750

-0.0086

-1.26%

盘后0.6899

+0.0149+2.21%

19:57 EDT

最高0.7000	最低0.6713	成交量109.89万
今开0.6900	昨收0.6836	日振幅4.20%
总市值1.53亿	流通市值1.42亿	总股本2.27亿
成交额74.95万	换手率0.52%	流通股本2.10亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VXRT","market":"US","secType":"STK","nameCN":"Vaxart, Inc","latestPrice":0.675,"timestamp":1721419200000,"preClose":0.6836,"halted":0,"volume":1098862,"hourTrading":{"tag":"盘后","latestPrice":0.6899,"preClose":0.675,"latestTime":"19:57 EDT","volume":101428,"amount":69143.726,"timestamp":1721433462737},"delay":0,"floatShares":210000000,"shares":226918467,"eps":-0.533496,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.0086,"latestTime":"07-19 16:00:00 EDT","open":0.69,"high":0.7,"low":0.6713,"amount":749508.4963740001,"amplitude":0.041984,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.533496,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721635200000},"adr":0,"adjPreClose":0.6836,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":0.6851,"preClose":0.6836,"latestTime":"09:28 EDT","volume":8499,"amount":5850.31163706,"timestamp":1721395724131},"postHourTrading":{"tag":"盘后","latestPrice":0.6899,"preClose":0.675,"latestTime":"19:57 EDT","volume":101428,"amount":69143.726,"timestamp":1721433462737},"volumeRatio":0.39601875846376866,"impliedVol":2.0756,"impliedVolPercentile":0.604},"requestUrl":"/m/hq/s/VXRT/tweets","defaultTab":"tweets","newsList":[{"id":"2449048597","title":"更新版 1-HilleVax 将停止开发婴儿诺如病毒疫苗；股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2449048597","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449048597?lang=zh_cn&edition=full","pubTime":"2024-07-08 23:02","pubTimestamp":1720450974,"startTime":"0","endTime":"0","summary":"     路透7月8日 - 周一，HilleVax   股价暴跌87.6%，创下1.75美元的历史新低，因为这家生物技术公司表示将停止开发用于婴儿的诺如病毒候选疫苗。HilleVax 公司表示，它将停止 HIL-214 在婴儿中的进一步开发，并将探索是否能在成人中继续进行同样的开发。HilleVax于今年1月从成都康华生物制品  获得了HIL-216在大中华区以外的开发和商业化 。诺如病毒是导致呕吐、腹泻和其他食源性疾病的主要原因之一。目前，莫德纳    和 Vaxart    也在开发诺如病毒疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4551","BK4548","BK4588","BK4568","BK4585","HLVX","VXRT","300841","BK4534","MRNA","BK4532","BK0239","BK4501","BK4533"],"gpt_icon":0},{"id":"2443666677","title":"获4.53亿美元巨资助力新冠口服疫苗研发后， Vaxart盘后股价飙涨60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2443666677","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443666677?lang=zh_cn&edition=full","pubTime":"2024-06-14 08:54","pubTimestamp":1718326478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技公司Vaxart股价在周四盘后交易中翻倍，股价飙升至52周新高，截至发稿，Vaxart股价在盘后涨近70%，报1.25美元。这一飞跃得益于该公司宣布通过快速反应伙伴关系平台获得了一项价值高达4.53亿美元的巨额项目奖，用于推进其口服COVID-19疫苗候选的评估工作。资金将分两个阶段提供：约6570万美元将立即用于支持研究的启动活动，而剩余的约3.872亿美元将在Vaxart与BARDA共同确定研究可以继续进行，并在研究的整个过程中逐步支付。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1135201.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","BK4139","VXRT"],"gpt_icon":1},{"id":"2443526106","title":"美国政府将为口服和鼻腔接种 COVID 疫苗的研究提供高达 5 亿美元的资助","url":"https://stock-news.laohu8.com/highlight/detail?id=2443526106","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443526106?lang=zh_cn&edition=full","pubTime":"2024-06-14 06:28","pubTimestamp":1718317707,"startTime":"0","endTime":"0","summary":"    路透6月13日 - 美国卫生与公众服务部 周四表示，它将提供高达 5 亿美元的资金用于中期试验，评估以鼻腔喷雾或药片形式接种疫苗以预防症状性 COVID-19 的情况。生物医学高级研究与发展管理局隶属于美国卫生与公共服务部，负责帮助企业开发医疗用品以应对公共卫生威胁。该项目将向Vaxart   提供高达4.53亿美元的资金，用于评估其口服COVID疫苗的研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","BK4585","BK4139","BK4009","BK4588","BNTX","HHS","BK4548","BK4568","VXRT"],"gpt_icon":0},{"id":"2435583530","title":"Vaxart 公司公布截至三月份的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2435583530","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435583530?lang=zh_cn&edition=full","pubTime":"2024-05-14 05:22","pubTimestamp":1715635365,"startTime":"0","endTime":"0","summary":"   * Vaxart Inc   报告，截至3月底的季度调整后每股亏损14美分，高于去年同期的每股-19美分。三位分析师对该季度的平均预期是每股亏损 14 美分。华尔街预期为每股-18美分至-10美分。* Vaxart Inc 公布的本季度每股收益为亏损 14 美分。* 该公司当季亏损 2442 万美元。* Vaxart Inc 本季度股价下跌了 45.8%，今年迄今为止上涨了 23.1%。华尔街对 Vaxart 公司 12 个月目标价的中位数为 5.00 美元  本摘要由 LSEG 5 月 13 日 09:22 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","VXRT"],"gpt_icon":0},{"id":"2434892170","title":"Vaxart Inc    预计每股亏损 14 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2434892170","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434892170?lang=zh_cn&edition=full","pubTime":"2024-05-11 05:39","pubTimestamp":1715377199,"startTime":"0","endTime":"0","summary":"   * Vaxart Inc    将于5月13日公布截至2024年3月31日的财报，预计季度收入将有所增长。* 根据LSEG的数据，3位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山南部的公司的营收将从去年同期的67.5万美元增至80万美元，增幅为18.5%。* LSEG 分析师对 Vaxart 公司的平均预期是每股亏损 14 美分。* 华尔街对 Vaxart Inc 的 12 个月目标价中位数为 5.00 美元，高于其 0.73 美元的最新收盘价。5月10日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXRT"],"gpt_icon":0},{"id":"2431348226","title":"Vaxart Inc    预计每股亏损 14 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431348226","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431348226?lang=zh_cn&edition=full","pubTime":"2024-04-30 19:42","pubTimestamp":1714477359,"startTime":"0","endTime":"0","summary":"   * Vaxart Inc    预计在5月2日公布截至2024年3月31日的业绩时，季度收入将有所增长(预计)。* 根据LSEG的数据，3位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山南部的公司的营收将从去年同期的67.5万美元增至80万美元，增幅为18.5%。* LSEG 分析师对 Vaxart 公司的平均预期是每股亏损 14 美分。* 华尔街对 Vaxart Inc 的 12 个月目标价中位数为 5.00 美元，高于其最新收盘价 0.71 美元。4月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXRT"],"gpt_icon":0},{"id":"2419495584","title":"Vaxart 公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2419495584","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419495584?lang=zh_cn&edition=full","pubTime":"2024-03-15 05:02","pubTimestamp":1710450130,"startTime":"0","endTime":"0","summary":"   * Vaxart Inc   报告，截至12月底的季度调整后每股亏损12美分，高于去年同期的每股-18美分。三位分析师对该季度的平均预期是每股亏损 14 美分。华尔街预期为每股-16美分至-13美分。* 营收同比增长 14650%，达到 325 万美元；分析师预期为 125 万美元。* Vaxart Inc 公布的本季度每股收益为亏损 12 美分。* 该公司当季亏损1738万美元。* 本季度，Vaxart Inc 的股价上涨了 97.3%。华尔街对 Vaxart 公司 12 个月目标价的中位数为 5.00 美元  本摘要由 LSEG 3 月 14 日 09:01 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXRT","BK4568","BK4139"],"gpt_icon":0},{"id":"2419794593","title":"Vaxart Inc    预计每股亏损 14 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2419794593","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419794593?lang=zh_cn&edition=full","pubTime":"2024-03-13 04:46","pubTimestamp":1710276372,"startTime":"0","endTime":"0","summary":"   * Vaxart Inc    将于3月14日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，2位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山南部的公司的营收预计将从一年前的2.2万美元增至125万美元，增幅为5581.8%。* LSEG 分析师对 Vaxart 公司的平均预期是每股亏损 14 美分。* 华尔街对 Vaxart Inc 的 12 个月目标价中位数为 5.00 美元，高于其最新收盘价 1.15 美元。3月12日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXRT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vaxart.com","stockEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0126},{"period":"3month","weight":-0.1067},{"period":"6month","weight":-0.0908},{"period":"1year","weight":-0.1498},{"period":"ytd","weight":0.1784}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vaxart, Inc.是一家专注于开发基于其专有的口服疫苗平台和直接作用抗病毒药物的口服重组蛋白疫苗的公司。Vaxart的口服疫苗旨在产生广泛而持久的免疫应答，可防范各种传染病，并可用于治疗慢性病毒感染和癌症。Vaxart的口服疫苗使用方便的室温稳定片剂进行施用，而不是通过注射。Vaxart认为片剂疫苗比注射疫苗更容易分发和服用，并能显著提高疫苗接种率。Vaxart的发展计划包括旨在防止诺如病毒，季节性流感和呼吸道合胞病毒（RSV）的口服片剂疫苗以及人乳头瘤病毒（HPV）的治疗性疫苗。通过收购其他公司，Vaxart还获得了抗病毒药物候选药物，包括teslexivir（BTA074），这是一种抗HPV病毒6型和11型引起的尖锐湿疣的抗病毒治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.875,"avgChangeRate":0.602214},{"month":2,"riseRate":0.375,"avgChangeRate":-0.02017},{"month":3,"riseRate":0.375,"avgChangeRate":-0.041288},{"month":4,"riseRate":0.375,"avgChangeRate":-0.010956},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.015057},{"month":6,"riseRate":0.444444,"avgChangeRate":0.200418},{"month":7,"riseRate":0.666667,"avgChangeRate":0.00457},{"month":8,"riseRate":0.5,"avgChangeRate":-0.017723},{"month":9,"riseRate":0.375,"avgChangeRate":-0.049034},{"month":10,"riseRate":0.125,"avgChangeRate":-0.161955},{"month":11,"riseRate":0.875,"avgChangeRate":0.099923},{"month":12,"riseRate":0.125,"avgChangeRate":-0.177549}],"exchange":"NASDAQ","name":"Vaxart, Inc","nameEN":"Vaxart, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vaxart, Inc(VXRT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Vaxart, Inc(VXRT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Vaxart, Inc,VXRT,Vaxart, Inc股票,Vaxart, Inc股票老虎,Vaxart, Inc股票老虎国际,Vaxart, Inc行情,Vaxart, Inc股票行情,Vaxart, Inc股价,Vaxart, Inc股市,Vaxart, Inc股票价格,Vaxart, Inc股票交易,Vaxart, Inc股票购买,Vaxart, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vaxart, Inc(VXRT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Vaxart, Inc(VXRT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}